Breaking: Eiger Biopharmaceuticals (EIGR) “Buy” Rating Reconfirmed by Piper Jaffray Today; The PT Given is $28.0000

May 18, 2018 - By Lindsey Sherman

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Logo

Eiger Biopharmaceuticals (EIGR) Rating Reaffirmed

Recently, In a report revealed to investors and clients on 18 May, Eiger Biopharmaceuticals (EIGR) shares have had their “Buy” Rating reaffirmed by stock research analysts at Piper Jaffray, who currently has a $28.0000 PT on company. This target by Piper Jaffray would suggest the possibile upside of 66.67 % from the close price.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Coverage

Among 6 analysts covering Eiger Biopharmaceuticals (EIGR), 6 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Eiger Biopharmaceuticals has $5300 highest and $17.0 lowest target. $30.83’s average target is 83.51% above currents $16.8 stock price. Eiger Biopharmaceuticals had 13 analyst reports since December 19, 2017 according to SRatingsIntel. Wedbush maintained the stock with “Buy” rating in Wednesday, April 18 report. Wedbush maintained it with “Buy” rating and $5300 target in Thursday, May 17 report. The rating was maintained by FBR Capital with “Buy” on Monday, May 14. The rating was maintained by Oppenheimer on Wednesday, March 21 with “Buy”. BTIG Research maintained the stock with “Buy” rating in Thursday, May 17 report. The stock of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) has “Buy” rating given on Friday, January 5 by Wedbush. The stock of Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) earned “Buy” rating by Oppenheimer on Monday, March 12. The rating was maintained by Piper Jaffray with “Buy” on Wednesday, March 21. The rating was maintained by Oppenheimer on Friday, May 11 with “Buy”. The rating was maintained by Wedbush with “Buy” on Tuesday, December 19.

The stock increased 41.77% or $4.95 during the last trading session, reaching $16.8. About 1.29 million shares traded or 1251.65% up from the average. Eiger BioPharmaceuticals, Inc. (EIGR) has declined 11.57% since May 18, 2017 and is downtrending. It has underperformed by 23.12% the S&P500.

Analysts await Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) to report earnings on August, 13. They expect $-0.98 earnings per share, up 26.32 % or $0.35 from last year’s $-1.33 per share. After $-0.84 actual earnings per share reported by Eiger BioPharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 16.67 % negative EPS growth.

Eiger BioPharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on providing various products for the treatment of orphan diseases in the United States. The company has market cap of $177.07 million. The Company’s product candidate pipeline includes Lonafarnib for the treatment of hepatitis delta virus infection; PEG-interferon Lambda-1a (Lambda) for HDV infection; Exendin 9-39 for post-bariatric hypoglycemia; and Ubenimex for the treatment of pulmonary arterial hypertension and lymphedema, which are under Phase II clinical trials. It currently has negative earnings.

More notable recent Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) news were published by: Benzinga.com which released: “Benzinga’s Daily Biotech Pulse: AstraZeneca’s Q1, Novartis-Amgen Migraine Drug Approved” on May 18, 2018, also Benzinga.com with their article: “24 Stocks Moving In Friday’s Pre-Market Session” published on May 18, 2018, Streetinsider.com published: “After-Hours Stock Movers 05/17: (QTNT) (VJET) (AFSI) Higher; (ARQL) (JWN) (AMAT) Lower (more…)” on May 17, 2018. More interesting news about Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) were released by: Benzinga.com and their article: “Benzinga’s Top Upgrades, Downgrades For May 9, 2018” published on May 09, 2018 as well as 247Wallst.com‘s news article titled: “Top Analyst Upgrades and Downgrades: AIG, Baxter, Cisco, Eiger Bio, Energy Transfer, Juniper, NOV, Phillips 66 …” with publication date: May 17, 2018.

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.